TransCode Therapeutics Announces Agreement with Triton Funds for Sale of Series A Convertible Preferred Stock TransCode Therapeutics NASDAQRNAZ

BOSTON, April 03, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. RNAZ (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a definitive securities purchase agreement with Triton Funds, LP for the sale of 60 shares of the Company’s Series A Convertible Preferred Stock (“Series A Preferred Stock”), each with a stated value of $10,000 per share (the “Stated Value”), for an aggregate purchase price of $500,000 in a registered direct offering. Each share of Series A Preferred Stock is convertible at any time after issuance at the…